Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANTI: BAY 1753011 in Congestive Heart Failure
2018-004059-18Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pecavaptan in heart failure (HF) and chronic heart failure (CHF) (4 arms), sponsored by Bayer. Primary endpoints: Change in body weight (Day 1 vs Day 30) and Change in serum creatinine (Day 1 vs Day 30). Started Feb 2019; status: completed.
02
Drugs
pecavaptan
03
Conditions
heart failure (HF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2018-004059-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004059-18.